Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 5/20 | 0.39 |
| ▸ | USP2 | O75604 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CCR6 | P51684 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5877548 | 0.97 | MAPT (0.42) | MAPTKMT2AALDH1A1KDM4EMEN1 | |
| SCHEMBL5875984 | 0.89 | STAT1 (0.40) | MAPTKMT2AALDH1A1KDM4EMEN1 | |
| SCHEMBL5876186 | 0.89 | CYP2C19 (0.42) | MAPTKMT2AALDH1A1KDM4EMEN1 | |
| SCHEMBL5877249 | 0.89 | STAT1 (0.39) | MAPTKMT2AALDH1A1KDM4EMEN1 | |
| SCHEMBL5876798 | 0.89 | KMT2A (0.39) | KMT2AALDH1A1KDM4EMEN1LMNA | |
| SCHEMBL5876034 | 0.88 | NR1H2 (0.36) | MAPTKMT2AALDH1A1KDM4EMEN1 | |
| SCHEMBL5877980 | 0.87 | KMT2A (0.39) | MAPTKMT2AALDH1A1MEN1LMNA | |
| SCHEMBL5876191 | 0.87 | ALDH1A1 (0.39) | MAPTKMT2AALDH1A1KDM4EMEN1 | |
| SCHEMBL5877142 | 0.86 | CYP2C19 (0.38) | MAPTKMT2AALDH1A1LMNAGAA | |
| SCHEMBL5876231 | 0.86 | CYP2C19 (0.39) | KMT2AALDH1A1KDM4ELMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7119115-B2 | Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology | AVENTIS PHARMA S.A. (FR) | 2006-10-10 | — | — | US | disclosed |
| US-20040162276-A1 | Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology | AVENTIS PHARMA S.A. (FR) | 2004-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162276-A1 | Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology | IDO1, IDO2, INMT | MAPT 1879/4885KMT2A 2326/4885ALDH1A1 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.